Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
- Submitting institution
-
University College London
- Unit of assessment
- 2 - Public Health, Health Services and Primary Care
- Output identifier
- 5472
- Type
- D - Journal article
- DOI
-
10.1016/S1470-2045(16)30172-3
- Title of journal
- The Lancet Oncology
- Article number
- -
- First page
- 1543
- Volume
- 17
- Issue
- 11
- ISSN
- 1470-2045
- Open access status
- Technical exception
- Month of publication
- September
- Year of publication
- 2016
- URL
-
-
- Supplementary information
-
https://ars.els-cdn.com/content/image/1-s2.0-S1470204516301723-mmc1.pdf
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
14
- Research group(s)
-
-
- Citation count
- 68
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -
